Significant Tumor Response to the Poly (ADP-ribose) Polymerase Inhibitor Olaparib in Heavily Pretreated Patient With Ovarian Carcinosarcoma Harboring a Germline RAD51D Mutation

被引：24
作者：
Chandran, Elias A. [1 ]
Kennedy, Ian [1 ]
机构：
[1] Waikato Dist Hlth Board, Pembroke St, Hamilton 3204, Waikato, New Zealand
来源：
JCO PRECISION ONCOLOGY | 2018年 / 2卷
关键词：
HOMOLOGOUS RECOMBINATION; SYNTHETIC LETHALITY; SOMATIC MUTATIONS; PARP-INHIBITION; RUCAPARIB; BRCANESS; CANCER; GENES; BRCA1;
D O I：
10.1200/PO.18.00253
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：1 / 4
页数：4
相关论文
共 20 条
  • [1] A synthetic lethal therapeutic approach: Poly(ADP) ribose polymerase inhibitors for the treatment of cancers deficient in DNA double-strand break repair
    Ashworth, Alan
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (22) : 3785 - 3790
  • [2] RAD51 foci as a functional biomarker of homologous recombination repair and PARP inhibitor resistance in germline BRCA-mutated breast cancer
    Cruz, C.
    Castroviejo-Bermejo, M.
    Gutierrez-Enriquez, S.
    Llop-Guevara, A.
    Ibrahim, Y. H.
    Gris-Oliver, A.
    Bonache, S.
    Morancho, B.
    Bruna, A.
    Rueda, O. M.
    Lai, Z.
    Polanska, U. M.
    Jones, G. N.
    Kristel, P.
    de Bustos, L.
    Guzman, M.
    Rodriguez, O.
    Grueso, J.
    Montalban, G.
    Caratu, G.
    Mancuso, F.
    Fasani, R.
    Jimenez, J.
    Howat, W. J.
    Dougherty, B.
    Vivancos, A.
    Nuciforo, P.
    Serres-Creixams, X.
    Rubio, I. T.
    Oaknin, A.
    Cadogan, E.
    Barrett, J. C.
    Caldas, C.
    Baselga, J.
    Saura, C.
    Cortes, J.
    Arribas, J.
    Jonkers, J.
    Diez, O.
    O'Connor, M. J.
    Balmana, J.
    Serra, V
    [J]. ANNALS OF ONCOLOGY, 2018, 29 (05) : 1203 - 1210
  • [3] Synthetic lethality of PARP inhibition in cancers lacking BRCA1 and BRCA2 mutations
    Dedes, Konstantin J.
    Wilkerson, Paul M.
    Wetterskog, Daniel
    Weigelt, Britta
    Ashworth, Alan
    Reis-Filho, Jorge S.
    [J]. CELL CYCLE, 2011, 10 (08) : 1192 - 1199
  • [4] Synthetic Lethality Triggered by Combining Olaparib with BRCA2-Rad51 Disruptors
    Falchi, Federico
    Giacomini, Elisa
    Masini, Tiziana
    Boutard, Nicolas
    Di Ianni, Lorenza
    Manerba, Marcella
    Farabegoli, Fulvia
    Rossini, Lara
    Robertson, Janet
    Minucci, Saverio
    Pallavicini, Isabella
    Di Stefano, Giuseppina
    Roberti, Marinella
    Pellicciari, Roberto
    Cavalli, Andrea
    [J]. ACS CHEMICAL BIOLOGY, 2017, 12 (10) : 2491 - 2497
  • [5] DNA recombination: the replication connection
    Haber, JE
    [J]. TRENDS IN BIOCHEMICAL SCIENCES, 1999, 24 (07) : 271 - 275
  • [6] The underlying mechanism for the PARP and BRCA synthetic lethality: Clearing up the misunderstandings
    Helleday, Thomas
    [J]. MOLECULAR ONCOLOGY, 2011, 5 (04): : 387 - 393
  • [7] Secondary Somatic Mutations Restoring RAD51C and RAD51D Associated with Acquired Resistance to the PARP Inhibitor Rucaparib in High-Grade Ovarian Carcinoma
    Kondrashova, Olga
    Nguyen, Minh
    Shield-Artin, Kristy
    Tinker, Anna V.
    Teng, Nelson N. H.
    Harrell, Maria I.
    Kuiper, Michael J.
    Ho, Gwo-Yaw
    Barker, Holly
    Jasin, Maria
    Prakash, Rohit
    Kass, Elizabeth M.
    Sullivan, Meghan R.
    Brunette, Gregory J.
    Bernstein, Kara A.
    Coleman, Robert L.
    Floquet, Anne
    Friedlander, Michael
    Kichenadasse, Ganessan
    O'Malley, David M.
    Oza, Amit
    Sun, James
    Robillard, Liliane
    Maloney, Lara
    Bowtell, David
    Giordano, Heidi
    Wakefield, Matthew J.
    Kaufmann, Scott H.
    Simmons, Andrew D.
    Harding, Thomas C.
    Raponi, Mitch
    McNeish, Iain A.
    Swisher, Elizabeth M.
    Lin, Kevin K.
    Scott, Clare L.
    [J]. CANCER DISCOVERY, 2017, 7 (09) : 984 - 998
  • [8] Evaluation of the methods to identify patients who may benefit from PARP inhibitor use
    Lim, Diana
    Ngeow, Joanne
    [J]. ENDOCRINE-RELATED CANCER, 2016, 23 (06) : R267 - R285
  • [9] Deficiency in the repair of DNA damage by homologous recombination and sensitivity to poly(ADP-ribose) polymerase inhibition
    McCabe, Nuala
    Turner, Nicholas C.
    Lord, Christopher J.
    Kluzek, Katarzyna
    Bialkowska, Aneta
    Swift, Sally
    Giavara, Sabrina
    O'Connor, Mark J.
    Tutt, Andrew N.
    Zdzienicka, Malgorzata Z.
    Smith, Graeme C. M.
    Ashworth, Alan
    [J]. CANCER RESEARCH, 2006, 66 (16) : 8109 - 8115
  • [10] Trapping of PARP1 and PARP2 by Clinical PARP Inhibitors
    Murai, Junko
    Huang, Shar-yin N.
    Das, Benu Brata
    Renaud, Amelie
    Zhang, Yiping
    Doroshow, James H.
    Ji, Jiuping
    Takeda, Shunichi
    Pommier, Yves
    [J]. CANCER RESEARCH, 2012, 72 (21) : 5588 - 5599
12